Keywords: Pfizer, Axitinib, Inlyta, USA, FDA advisory, Kidney cancer

Pfizer’s axitinib favored by FDA panel

Article | 09 December 2011

Print This

Global drugs behemoth Pfizer (NYSE: PFE) says that the U.S. Food and Drug Administration’s Oncologic Drugs Advisory ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in